Aspira Women s Health Inc (AWH)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
Profitability not reached inspite of impressive Revenues at in the most recent fiscal period
company announced fourth quarter of 2022 operating loss of $-5.601 millions
Published Apr 02 2023
Goran Soko / CSIMarket.com Contributer
![Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
For the most recent fiscal period AWH lost money of $-0.04 per share compare to $-0.08 a year ago and from $-0.04 per share from the preceding reporting period. Revenues inched up widely by 16.316 % to $2.15 millions from $1.85 millions in the corresponding reporting period a year ago and sequentially Revenues surged by 3.909 % from $2.07 millions.
In the most recent fiscal period Aspira Women S Health Inc reported net loss of $-5.101 million, instead of deficit of $-8.961 millions in the corresponding reporting period a year ago.
Furthermore, the Aspira Women S Health Inc noted as well net loss of $-27.17 millions and for the financial year 2022, Revenues of $8.18 millions.
Biotechnology & Pharmaceuticals Aspira Women S Health Inc has decreased it's loss per share to $-0.23 from $-0.28 in the preceding fiscal year, while Revenues improved by 20.14 % from $6.81 millions a year ago.
Aspira Women S Health Inc is expected to report next financial earnings on May 10, 2023.